Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Establishment and validation of a comprehensive non-invasive CNS tumor classifier and biomarker through circulating cell-free DNA analysis

EF 2022-23

Résumé
Tumours of the brain and central nervous system are significant causes of morbidity and mortality around the world. Currently, standard of care for the diagnosis of these tumors require tissue sampling obtained by biopsy or surgery for histopathological analysis, which are invasive and carry significant risks. Moreover, tracking the effectiveness of treatments is often challenging. Epigenetics, the study of the modification of DNA through a process called DNA methylation, is an evolving area of research aimed at diagnosing and classifying intracranial tumors based off of their pattern of methylation; however, this approach is also hindered by the requirement for tumor tissue. Recent work has uncovered "circulating cell-free tumor DNA" (ctDNA) within the plasma of patients suffering from brain tumors; however due to the minute amount of DNA available, rote sequencing of these ctDNA fragments has traditionally been limited. The Zadeh lab and its affiliates have developed a novel technique of capturing the methylation sequences of ctDNA called "cell-free methylated DNA immunoprecipitation combined with deep sequencing" (cfMeDIP-seq) which has the potential to allow for the non-invasive detection and discrimination of intracranial tumors. The purpose of this project is to validate the use of cfMeDIP-seq for both the diagnosis and clinical follow up of intracranial tumors through a prospective real-world clinical study.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475624
Name
Ajisebutu Andrew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Establishment and validation of a comprehensive non-invasive CNS tumor classifier and biomarker through circulating cell-free DNA analysis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biomarker; Brain Tumor; Cancer; Epigenetics; Genetics; Glioma; Neurosciences
Abstract
Tumours of the brain and central nervous system are significant causes of morbidity and mortality around the world. Currently, standard of care for the diagnosis of these tumors require tissue sampling obtained by biopsy or surgery for histopathological analysis, which are invasive and carry significant risks. Moreover, tracking the effectiveness of treatments is often challenging. Epigenetics, the study of the modification of DNA through a process called DNA methylation, is an evolving area of research aimed at diagnosing and classifying intracranial tumors based off of their pattern of methylation; however, this approach is also hindered by the requirement for tumor tissue. Recent work has uncovered "circulating cell-free tumor DNA" (ctDNA) within the plasma of patients suffering from brain tumors; however due to the minute amount of DNA available, rote sequencing of these ctDNA fragments has traditionally been limited. The Zadeh lab and its affiliates have developed a novel technique of capturing the methylation sequences of ctDNA called "cell-free methylated DNA immunoprecipitation combined with deep sequencing" (cfMeDIP-seq) which has the potential to allow for the non-invasive detection and discrimination of intracranial tumors. The purpose of this project is to validate the use of cfMeDIP-seq for both the diagnosis and clinical follow up of intracranial tumors through a prospective real-world clinical study.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ajisebutu, Andrew
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~